Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects
- 1 December 2000
- journal article
- clinical trial
- Published by Wiley
- Vol. 50 (6) , 543-552
- https://doi.org/10.1046/j.1365-2125.2000.00297.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetics, Pharmacodynamics, and Safety of Microencapsulated Octreotide Acetate in Healthy SubjectsThe Journal of Clinical Pharmacology, 2000
- Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patientsMetabolism, 1996
- Sandostatin® LAR® (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationshipsMetabolism, 1996
- Clinical Pharmacokinetics of OctreotideClinical Pharmacokinetics, 1993
- Growth Hormone and Diabetes mellitusHormone Research, 1993
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Radioimmunoassay of the Somatomedins/Insulin-like Growth FactorsPublished by Springer Nature ,1987
- Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma.Journal of Clinical Investigation, 1986
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Estimation of population characteristics of pharmacokinetic parameters from routine clinical dataJournal of Pharmacokinetics and Biopharmaceutics, 1977